That’s sage advice. I would ask how the optimism has worked thus far. You can’t compare Cytodyn to any other company as each are unique.
I think any research would show difficulty in finding any management team that has bungled more positive potential than this one.
The biggest trial and the impetus for PRO-140 was HIV and they couldn’t even get the application filed correctly. I’ve been involved, much less now, since 2017 which is MUCH longer than most. Perhaps not all but many have not experienced what some of us have and the continued failures.
People are free to invest as they wish AND investors are free to praise/criticize as well. This turned from a sound investment when I was in and buying down at the $.30 level. I quickly found that after selling most in the $6 range that I’ve had much more success flipping this stock on the Nader PR merry go round. Perhaps one day he’ll get it right.
I will flip this again today prior to the next “call” then dump it. I don’t short stocks...don’t even have the capability. Some have tried to parse my DD and predictions but if it’s not to the penny, somehow I’ve called it wrong. You’ll see by following my posts that my analysis showed this plummeting into the $2 range, which it did. I’ve also assessed a price point of $1.50. Each failed PR cycle brings a new low. This temporary sugar high might last through midweek but sans approval or sale of the product, it’s going down further. That’s the pattern...it doesn’t take a genius to see it. The price is propped up by hope, speculation and confusing communications. Sooner or later, the fiddler will come knocking
Best to you in all your investments-
Grip
Market Data 
Markets 
AI
